Psychedelics closer to commercialization; Compass far and away the leader

May 23, 2024 · 13m 50s
Psychedelics closer to commercialization; Compass far and away the leader
Description

Analyst https://seekingalpha.com/author/alexander-carchidi?source=ie_podcast:psychedelics_closer_to_commercialization_compass_leader discusses positive news coming out of psychedelic space (1:00). Recent earnings show companies moving closer to commercialization (3:35). https://seekingalpha.com/symbol/CYBN?source=ie_podcast:psychedelics_closer_to_commercialization_compass_leader and Atai developments; clinical studies and regulatory relief (5:25)....

show more
Analyst Alex Carchidi discusses positive news coming out of psychedelic space (1:00). Recent earnings show companies moving closer to commercialization (3:35). Cybin and Atai developments; clinical studies and regulatory relief (5:25). Why now is the time to get into the space; ranking Compass and MindMed above the rest (8:00). Proper metrics and diversified pipelines (10:20).

Show Notes:
Psychedelic therapy: FDA panel to review first ever MDMA-assisted PTSD treatment
De-Risking Psychedelics: Compass Pathways, Cybin And Atai
Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets.
COMPASS Pathways Q1 2024 Earnings Call Transcript

Episode transcripts

For full access to analyst ratings, stock quant scores as well as dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

Register for Seeking Alpha's Investing Summit (with your podcast discount code!)
show less
Information
Author Seeking Alpha
Website seekingalpha.com
Tags

Looks like you don't have any active episode

Browse Spreaker Catalogue to discover great new content

Current

Podcast Cover

Looks like you don't have any episodes in your queue

Browse Spreaker Catalogue to discover great new content

Next Up

Episode Cover Episode Cover

It's so quiet here...

Time to discover new episodes!

Discover
Your Library
Search